GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Global Corp (ASX:AVR) » Definitions » Ending Cash Position

Anteris Technologies Global (ASX:AVR) Ending Cash Position : A$111.25 Mil (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Anteris Technologies Global Ending Cash Position?

Anteris Technologies Global's Ending Cash Position for the quarter that ended in Dec. 2024 was A$111.25 Mil.

Anteris Technologies Global's quarterly Ending Cash Position declined from Dec. 2023 (A$31.38 Mil) to Jun. 2024 (A$10.92 Mil) but then increased from Jun. 2024 (A$10.92 Mil) to Dec. 2024 (A$111.25 Mil).

Anteris Technologies Global's annual Ending Cash Position increased from Dec. 2022 (A$13.92 Mil) to Dec. 2023 (A$31.38 Mil) and increased from Dec. 2023 (A$31.38 Mil) to Dec. 2024 (A$111.25 Mil).

Anteris Technologies Global Ending Cash Position Historical Data

The historical data trend for Anteris Technologies Global's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies Global Ending Cash Position Chart

Anteris Technologies Global Annual Data
Trend Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.45 21.59 13.92 31.38 111.25

Anteris Technologies Global Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.92 19.98 31.38 10.92 111.25

Anteris Technologies Global Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Anteris Technologies Global's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=33.3+77.953
=111.25

Anteris Technologies Global's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=12.203+99.05
=111.25

Anteris Technologies Global Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Anteris Technologies Global's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Anteris Technologies Global Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Global Corp (ASX:AVR) » Definitions » Ending Cash Position
Comparable Companies
ASX:IMR ASX:ARX ASX:4DX ASX:EMV ASX:SOM ASX:IPD ASX:RSH ASX:COV ASX:CMP ASX:CVB ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE
Traded in Other Exchanges
N/A
Address
9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Website
https://www.anteristech.com
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis - a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.